重大非心脏手术前继续与停用肾素-血管紧张素系统抑制剂:Stop-or-Not随机临床试验
该随机临床试验在法国40家医院纳入2222例长期服用肾素-血管紧张素系统抑制剂(RASI)并拟行重大非心脏手术的患者,比较继续用药至手术当日与术前48小时停药两种策略。结果显示两组28天内全因死亡和主要术后并发症发生率均为22%(风险比1.02,95%CI 0.87-1.19;P=0.85),继续用药组术中低血压发生率高于停药组(54% vs 41%,风险比1.31,95%CI 1.19-1.44)。
要点
- 重大非心脏手术前继续RASI与停药相比,28天全因死亡和主要术后并发症发生率无显著差异(22% vs 22%)。
- 继续RASI组术中低血压发生率高于停药组(54% vs 41%,风险比1.31,95%CI 1.19-1.44)。
- 两组其他次要结局无差异。
核心结论
- 在重大非心脏手术患者中,术前继续RASI策略与停药策略相比,术后并发症发生率未升高。
研究设计与样本
- 随机临床试验,纳入至少服用RASI 3个月并拟行重大非心脏手术的患者,2018年1月至2023年4月在法国40家医院进行。
- 患者随机分为继续用药至手术当日组(n=1107)和术前48小时停药组(即术前3天服用末次剂量)(n=1115)。
- 共2222例患者,平均年龄67岁(SD 10岁),65%为男性,基线时46%服用血管紧张素转换酶抑制剂,54%服用血管紧张素受体阻滞剂。
主要发现
- 主要结局(28天内全因死亡和主要术后并发症复合终点)发生率:停药组22%(245/1115)vs 继续组22%(247/1107),风险比1.02(95%CI 0.87-1.19;P=0.85)。
- 术中低血压发生率:停药组41% vs 继续组54%,风险比1.31(95%CI 1.19-1.44)。
- 其他试验结局无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Before surgery, the best strategy for managing patients who are taking renin-angiotensin system inhibitors (RASIs) (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) is unknown. The lack of evidence leads to conflicting guidelines. OBJECTIVE: To evaluate whether a continuation strategy vs a discontinuation strategy of RASIs before major noncardiac surgery results in decreased complications at 28 days after surgery. DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial that included patients who were being treated with a RASI for at least 3 months and were scheduled to undergo a major noncardiac surgery between January 2018 and April 2023 at 40 hospitals in France. INTERVENTION: Patients were randomized to continue use of RASIs (n = 1107) until the day of surgery or to discontinue use of RASIs 48 hours prior to surgery (ie, they would take the last dose 3 days before surgery) (n = 1115). MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause mortality and major postoperative complications within 28 days after surgery. The key secondary outcomes were episodes of hypotension during surgery, acute kidney injury, postoperative organ failure, and length of stay in the hospital and intensive care unit during the 28 days after surgery. RESULTS: Of the 2222 patients (mean age, 67 years [SD, 10 years]; 65% were male), 46% were being treated with angiotensin-converting enzyme inhibitors at baseline and 54% were being treated with angiotensin receptor blockers. The rate of all-cause mortality and major postoperative complications was 22% (245 of 1115 patients) in the RASI discontinuation group and 22% (247 of 1107 patients) in the RASI continuation group (risk ratio, 1.02 [95% CI, 0.87-1.19]; P = .85). Episodes of hypotension during surgery occurred in 41% of the patients in the RASI discontinuation group and in 54% of the patients in the RASI continuation group (risk ratio, 1.31 [95% CI, 1.19-1.44]). There were no other differences in the trial outcomes. CONCLUSIONS AND RELEVANCE: Among patients who underwent major noncardiac surgery, a continuation strategy of RASIs before surgery was not associated with a higher rate of postoperative complications than a discontinuation strategy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03374449.
引用
- Legrand M, Falcone J, Cholley B, et al. Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery: The Stop-or-Not Randomized Clinical Trial. JAMA. 2024. PMID: 39212270. doi:10.1001/jama.2024.17123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。